Hämodynamische Effekte einer Immunadsorption mit nachfolgender Immunglobulin-G-Substitution bei Patienten mit dilatativer Kardiomyopathie – Ergebnisse einer prospektiven und randomisierten StudieMarcus Dörr161.171.21.2.11.2.21.2.381.2.3.11.2.3.21.2.3.2.191.2.3.2.21.2.3.2.31011121.2.3.313567#406569#39961#37141.2.3.415542#2931.2.4161.2.5171.2.5.11.2.5.1.11.2.5.1.21819201.2.5.1.2.11.2.5.1.2.2211.2.5.1.3221.2.5.21.2.5.2.11.2.5.2.2232242.12.2253263.13.1.1273.1.228637#343293.1.2.130489#4893.2313.2.13.2.23.2.3323.3333.3.13.3.234621#3593.4353.4.136396#2433749#3329#3147#3329#33108#3188#20106#3188#203.4.23873#100393.4.3403.4.43.4.5414424.1456#36943460#368444.245623#36846623#369586#32847623#36648507#37149623#36850627#369623#32151623#36652641#34653623#35754623#3604.355623#36056623#369624#31957623#265623#265584.459623#3694.560623#36961623#3694.6624.7634.84.9645655.166676869705.2717273747576777879805.3815.482838468586 7 LITERATURVERZEICHNIS8 ANHANGAbkürzungsverzeichnisDanksagungLebenslaufdeInhaltsverzeichnisHilfe 7 LITERATURVERZEICHNIS [1] Richardson, P.; McKenna, W.; Bristow, M.; Maisch, B.; Mautner, B.; O'Con-nell, J.; Olsen, E.; Thiene, G.; Goodwin, J.; Gyarfas, I.; Martin, I. und Nordet, P. (1996): Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardio-myopathies, Circulation, (Band 93), No. 5, Seite 841-2. [2] Maisch, B. (1998): Einteilung der Kardiomyopathien nach der WHO/ISFC Task Force - Mehr Fragen als Antworten ?, Medizinische Klinik, (Band 93), No. 3, Seite 199-209. [3] Seimann, CE; McKenna, WJ und Watkins, HC (1992): Molecular genetic approaches to di-agnosis and management of hypertrophic cardiomyopathy, Braunwald, E, A Textbook of Cardiovascular Medi-cine, Seite 77-83, WB Saunders Co.,

New York

. [4] Dec, G. W. und Fuster, V. (1994): Idiopathic dilated cardiomyopathy, N Engl J Med, (Band 331), No. 23, Seite 1564-75. [5] Mestroni, L.; Miani, D.; Di Lenarda, A.; Silvestri, F.; Bussani, R.; Filippi, G. und Camerini, F. (1990): Clinical and pathologic study of familial dilated cardiomyopathy, Am J Cardiol, (Band 65), No. 22, Seite 1449-53. [6] Ferrans, V. J. (1989): Pathologic anatomy of the dilated cardiomyopathies, Am J Cardiol, (Band 64), No. 6, Seite 9C-11C. [7] Tazelaar, H.D. und Billingham, M.E. (1986): Leukocytic infiltrates in idiopathic dilated cardiomyopathy: a source of confusion with active myocarditis, Am J Surg Pathol, (Band 10), Seite 405-412. [8] Towbin, J. A.; Hejtmancik, J. F.; Brink, P.; Gelb, B.; Zhu, X. M.; Chamber-lain, J. S.; McCabe, E. R. und Swift, M. (1993): X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus, Circulation, (Band 87), No. 6, Seite 1854-65. [9] Thierfelder, L. (1998): Genetik der dilatativen Kardiomyopathie, Medizinische Klinik, (Band 93), No. 3, Seite 210-214. [10] Caforio, A. L.; Baboonian, C. und McKenna, W. J. (1997): Postviral autoimmune heart disease - fact or fiction ?, Eur Heart J, (Band 18), No. 7, Seite 1051-5. [11] Kühl, U.; Noutsias, M.; Seeberg, B. und Schultheiss, H. P. (1996): Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopa-thy, Heart, (Band 75), No. 3, Seite 295-300. [12] Hufnagel, G.; Pankuweit, S.; Richter, A.; Schonian, U. und Maisch, B. (2000): The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results, Herz, (Band 25), No. 3, Seite 279-85. [13] Kandolf, R. (1998): Enterovirale Myokarditis und dilatative Kardiomyopathie, Medizinische Klinik, (Band 93), No. 3, Seite 215-222. [14] Pankuweit, S.; Hufnagel, G. und Eckhardt, H. (1998): Kardiotrope DNA-Viren und Bakterien in der Pathogenese der dilatativen Kardiomyopathie mit und ohne Entzün-dung, Medizinische Klinik, (Band 93), No. 3, Seite 223-228. [15] Cetta, F. und Michels, V. (1995): The autoimmune basis of dilated cardiomyopathy, Ann Med, (Band 27), No. 2, Seite 169-73. [16] Kanda, T.; Yokoyama, T.; Suzuki, T. und Murata, K. (1992): Functional abnormalities of circulating natural killer cell, Tohoku J Exp Med, (Band 168), No. 3, Seite 529-37. [17] Schultheiss, H. P. (1989): The significance of autoantibodies against the ADP/ATP carrier for the pathogenesis of myocarditis and dilated cardiomyopathy - clinical and experi-mental data, Springer Semin Immunopathol, (Band 11), No. 1, Seite 15-30. [18] Caforio, A. L.; Grazzini, M.; Mann, J. M.; Keeling, P. J.; Bottazzo, G. F.; McKenna, W. J. und Schiaffino, S. (1992): Identification of alpha- and beta-cardiac myosin heavy chain iso-forms as major autoantigens in dilated cardiomyopathy, Circulation, (Band 85), No. 5, Seite 1734-42. [19] Maisch, B.; Herzum, M.; Hufnagel, G.; Bethge, C. und Schonian, U. (1995): Immunosuppressive treatment for myocarditis and dilated cardiomyopathy, Eur Heart J, (Band 16 Suppl O), Seite 153-61. [20] Kühl, U.; Melzner, B.; Schafer, B.; Schultheiss, H. P. und Strauer, B. E. (1991): The Ca-channel as cardiac autoantigen, Eur Heart J, (Band 12 Suppl D), Seite 99-104. [21] Fu, M; Schulze, W.; Wallukat, G.; Hjalmarson, A. und Hoebeke, J. (1996): A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyo-cytes by active immunization after 6 month in rabbits., Clin Immunol Immunopathol, (Band 78), Seite 203-207. [22] Limas, C. J. und Limas, C. (1991): Beta-adrenoceptor antibodies and genetics in dilated cardiomyopathy - an overview and review, Eur Heart J, (Band 12 Suppl D), Seite 175-7. [23] Wallukat, G.; Nissen, E.; Morwinski, R. und Müller, J. (2000): Autoantikörper gegen Beta- und muskarinerge Rezeptoren bei Kardiomyopathie, Herz, (Band 25), No. 3, Seite 261-266. [24] Liu, H.R.; Zhao, R.R.; Zhi, J.M.; Wu, W.B. und Fu, M.L. (1999): Screening of serum autoantibodies to cardiac beta1-adrenoceptors and M2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages, Autoimmunity, (Band 29), No. 1, Seite 43-51. [25] Wallukat, G.; Wollenberger, A.; Morwinski, R. und Pitschner, H. F. (1995): Anti beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of pa-tients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops, J Mol Cell Cardiol, (Band 27), No. 1, Seite 397-406. [26] Krause, E. G.; Bartel, S.; Beyerdorfer, I. und Wallukat, G. (1996): Activation of cyclic AMP-dependent protein kinase in cardiomyocytes by anti-beta 1-adrenoceptor autoantibodies from patients with idiopathic dilated cardiomyopathy, Blood Press Suppl, (Band 3), Seite 37-40. [27] Wallukat, G.; Kayser, A. und Wollenberger, A. (1995): The beta1-adrenoceptor as antigen: functional aspects, Eur Heart J, (Band 16 Suppl O), Seite 85-8. [28] Matsui, S.; Fu, M.L. und Hyase, M. (1999): Active immunization of combined beta1-adrenoceptor and M2-muscarinic receptor peptides induces cardiac hy-perthrophy in rabbits, J Card Fail, (Band Sep 5), No. 3, Seite 246-54. [29] Matsui, S. und Fu, M.L. (1998): Myocardial injury due to G-Protein couples receptor-autoimmunity, Jpn Heart J, (Band 39), No. 3, Seite 261-74. [30] Matsumori, A. (1996): Cytokines in myocarditis and cardiomyopathies, Curr Opin Cardiol, (Band 11), No. 3, Seite 302-9. [31] Torre-Amione, G.; Kapadia, S.; Benedict, C.; Oral, H.; Young, J. B. und Mann, D. L. (1996): Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD), J Am Coll Cardiol, (Band 27), No. 5, Seite 1201-6. [32] Ferrari, R.; Bachetti, T.; Confortini, R.; Opasich, C.; Febo, O.; Corti, A.; Cassani, G. und Visioli, O. (1995): Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure, Circulation, (Band 92), No. 6, Seite 1479-86. [33] Aukrust, P.; Ueland, T.; Lien, E.; Bendtzen, K.; Muller, F.; Andreassen, A. K.; Nordoy, I.; Aass, H.; Espevik, T.; Simonsen, S.; Froland, S. S. und Gullestad, L. (1999): Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardio-myopathy, Am J Cardiol, (Band 83), No. 3, Seite 376-82. [34] Cain, B. S.; Meldrum, D. R.; Dinarello, C. A.; Meng, X.; Joo, K. S.; Baner-jee, A. und Harken, A. H. (1999): Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function, Crit Care Med, (Band 27), No. 7, Seite 1309-18. [35] Torre-Amione, G.; Vooletich, M. T. und Farmer, J. A. (2000): Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications, Drugs, (Band 59), No. 4, Seite 745-51. [36] Plenz, G.; Song, Z. F.; Reichenberg, S.; Tjan, T. D.; Robenek, H. und Deng, M. C. (1998): Left-ventricular expression of interleukin-6 messenger-RNA higher in idiopathic di-lated than in ischemic cardiomyopathy, Thorac Cardio-vasc Surg, (Band 46), No. 4, Seite 213-6. [37] Kosar, F.; Varol, E.; Ileri, M.; Ayaz, S.; Hisar, I. und Kisacik, H. (1999): Circulating cytokines and complements in chronic heart failure, Angiology, (Band 50), No. 5, Seite 403-8. [38] Pagani, F. D.; Baker, L. S.; Hsi, C.; Knox, M.; Fink, M. P. und Visner, M. S. (1992): Left ventricular sys-tolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs, J Clin Invest, (Band 90), No. 2, Seite 389-98. [39] Gulick, T.; Chung, M. K.; Pieper, S. J.; Lange, L. G. und Schreiner, G. F. (1989): Interleukin-1 and tu-mor necrosis factor inhibit cardiac myocyte beta-adrenergic responsive-ness, Proc Natl Acad Sci U S A, (Band 86), No. 17, Seite 6753-7. [40] Hegewisch, S.; Weh, H. J. und Hossfeld, D. K. (1990): TNF-induced cardiomyopa-thy, Lancet, (Band 335), No. 8684, Seite 294-5. [41] Garza, H.; Garzon, G. und Stetson, S.J. (2000): Tumor necrosis factor-alpha: a media-tor in the pathogenesis of cardiac insuffiency, Arch Inst Cardiol Mex, (Band 69), No. 5, Seite 462-468. [42] Parissis, J. T.; Venetsanou, K. F.; Mentzikof, D. G.; Ziras, N. G.; Kefalas, C. G. und Karas, S. M. (1999): Tumor necrosis factor-alpha serum activity during treatment of acute decom-pensation of cachectic and non-cachectic patients with advanced congestive heart failure, Scand Cardiovasc J, (Band 33), No. 6, Seite 344-50. [43] Müller-Werdan, U.; Engelmann, H. und Werdan, K. (1998): Cardiodepression by tumor necrosis factor-alpha, Eur Cytokine Netw, (Band 9), No. 4, Seite 689-91. [44] Comini, L.; Bachetti, T.; Agnoletti, L.; Gaia, G.; Curello, S.; Milanesi, B.; Volterrani, M.; Parrinello, G.; Ceconi, C.; Giordano, A.; Corti, A. und Ferrari, R. (1999): Induction of func-tional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha, Eur Heart J, (Band 20), No. 20, Seite 1503-13. [45] Narula, J.; Kolodgie, F. D. und Virmani, R. (2000): Apoptosis and cardiomyopa-thy, Curr Opin Cardiol, (Band 15), No. 3, Seite 183-8. [46] Ferrari, R.; Corti, A. und Tiziana, B. (1995): Tumor Necrosis Alpha in Heart Fail-ure, Heart Failure, (Band Aug/Sept), Seite 142-147. [47] Roig, E.; Orus, J.; Pare, C.; Azqueta, M.; Filella, X.; Perez-Villa, F.; Heras, M. und Sanz, G. (1998): Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardio-myopathy, Am J Cardiol, (Band 82), No. 5, Seite 688-90, A8. [48] Boura, P.; Lefkos, N.; Boudonas, G.; Kountouras, J.; Zacharioudaki, E.; Efthimiadis, A. und Tsapas, G. (1999): Antigenic stimulation in T-cell cultures in cardiomyopathies: differences in cytokine profiles, Eur J Immunogenet, (Band 26), No. 4, Seite 285-91. [49] Rauchhaus, M.; Coats, A. J.; Anker, S. D.; Niebauer, J.; Volk, H. D.; Kemp, M.; Dominguez, M.; Schumann, R. R. und Poole-Wilson, P. A. (2000): The endotoxin-lipoprotein hypothesis - Endotoxin and immune activation in chronic heart failure: a prospective cohort study, Lancet, (Band 356), No. 9233, Seite 930-3. [50] Duchman, S. M.; Thohan, V.; Kalra, D. und Torre-Amione, G. (2000): Endothelin-1: a new target of thera-peutic intervention for the treatment of heart failure, Curr Opin Cardiol, (Band 15), No. 3, Seite 136-40. [51] Pousset, F.; Isnard, R.; Lechat, P.; Kalotka, H.; Carayon, A.; Maistre, G.; Escolano, S.; Thomas, D. und Komajda, M. (1997): Prognostic value of plasma endo-thelin-1 in patients with chronic heart failure, Eur Heart J, (Band 18), No. 2, Seite 254-8. [52] Samsonov, M. (1993): Anaphylatoxine in dilated cardiomyopathy, J Intern Med, (Band 234), Seite 139-42. [53] Narula, J.; Haider, N.; Virmani, R.; DiSalvo, T. G.; Kolodgie, F. D.; Hajjar, R. J.; Schmidt, U.; Semigran, M. J.; Dec, G. W. und Khaw, B. A. (1996): Apoptosis in myocytes in end-stage heart failure, N Engl J Med, (Band 335), No. 16, Seite 1182-9. [54] Felix, S.B. (1996): Prognose der Herzinsuffizienz - Bedeutung der medikamentösen Thera-pie, Z Kardiol, (Band 85), No. Suppl 4, Seite 1-7. [55] Felix, S.B. und Baumann, G. (1996): Herzinsuffizienz, Stobbe, H. und Baumann, G., Innere Medizin, Seite 168-190, Urban & Fischer. [56] Bristow, M. R.; Anderson, F. L.; Port, J. D.; Skerl, L.; Hershberger, R. E.; Larrabee, P.; O'Connell, J. B.; Renlund, D. G.; Volkman, K.; Murray, J. und et al. (1991): Differences in beta-adrenergic neuroeffector mechanisms in ischemic, Circulation, (Band 84), No. 3, Seite 1024-39. [57] Schrier, R.W. und Abraham, W.T. (1999): Hormones and hemodynamics in heart failure, N Eng J Med, (Band 341), Seite 577-585. [58] Manolio, T. A.; Baughman, K. L.; Rodeheffer, R.; Pearson, T. A.; Bristow, J. D.; Michels, V. V.; Abelmann, W. H. und Harlan, W. R. (1992): Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop, Am J Cardiol, (Band 69), No. 17, Seite 1458-66. [59] Hellige, G.; Spieckermann, P.G. und Baumann, G. (1997): Herzinsuffizienz - Fortschritt in Diagnostik und Therapie (Band 1), Arcis-Verlag,

München

. [60] Kienzle, M. G.; Ferguson, D. W.; Birkett, C. L.; Myers, G. A.; Berg, W. J. und Mariano, D. J. (1992): Clinical, hemodynamic and sympathetic neural correlates of heart rate vari-ability in congestive heart failure, Am J Car-diol, (Band 69), No. 8, Seite 761-7. [61] Keogh, A. M.; Baron, D. W. und Hickie, J. B. (1990): Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplanta-tion, Am J Cardiol, (Band 65), No. 13, Seite 903-8. [62] Anker, S. D. und Cicoira, M. (1999): [Chronic heart failure and cardiac cachexia and links between the endocrine and immune systems], Z Kardiol, (Band 88 Suppl 3), Seite S18-S23. [63] Roig, E.; Perez-Villa, F.; Morales, M.; Jimenez, W.; Orus, J.; Heras, M. und Sanz, G. (2000): Clinical impli-cations of increased plasma angiotensin II despite ACE inhibitor therapy in pa-tients with congestive heart failure, Eur Heart J, (Band 21), No. 1, Seite 53-7. [64] Maeda, K.; Tsutamoto, T.; Wada, A.; Mabuchi, N.; Hayashi, M.; Tsutsui, T.; Ohnishi, M.; Sawaki, M.; Fujii, M.; Matsumoto, T. und Kinoshita, M. (2000): High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure, J Am Coll Car-diol, (Band 36), No. 5, Seite 1587-93. [65] Janicki, J. S.; Weber, K. T. und McElroy, P. A. (1988): Use of the cardiopulmonary exercise test to evaluate the patient with chronic heart failure, Eur Heart J, (Band 9 Suppl H), Seite 55-8. [66] Winter, U.J. et al. (1994): Klinischer Wert der modernen, computerisierten Ergospirometrie, Mager, G. und Winter, U.J., Belastungsuntersuchungen bei Herz-, Kreislauf-, Gefäß- und Lungenerkrankungen, Seite 56-75,

Stuttgart

. [67] Weber, K.T. und Janicki, J.S. (1991): Exercise evaluation of cardiorespiratory function, Cardiology I (Band Chapter 32), Seite 4202-4212,

Philadelphia

. [68] Szlachcic, J.; Massie, B. M.; Kramer, B. L.; Topic, N. und Tubau, J. (1985): Correlates and prog-nostic implication of exercise capacity in chronic congestive heart fail-ure, Am J Cardiol, (Band 55), No. 8, Seite 1037-42. [69] de Vries, R. J.; van Veldhuisen, D. J.; Dunselman, P. H.; van der Veer, N. und Crijns, H. J. (1997): Physiological parameters during the initial stages of cardiopulmonary exer-cise testing in patients with chronic heart failure. Their value in the assessment of clinical severity and prognosis, Eur Heart J, (Band 18), No. 12, Seite 1921-30. [70] Meyer, K. (1999): Exercise training in chronic heart failure: is it really safe ?, Eur Heart J, (Band 20), No. 12, Seite 851-3. [71] Kiilavuori, K.; Naveri, H.; Leinonen, H. und Harkonen, M. (1999): The effect of physical training on hor-monal status and exertional hormonal response in patients with chronic conges-tive heart failure, Eur Heart J, (Band 20), No. 6, Seite 456-64. [72] Hambrecht, R.; Niebauer, J.; Fiehn, E.; Kalberer, B.; Offner, B.; Hauer, K.; Riede, U.; Schlierf, G.; Kubler, W. und Schuler, G. (1995): Physical training in patients with sta-ble chronic heart failure: Effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles, J Am Coll Car-diol, (Band 25), No. 6, Seite 1239-49. [73] Hoppe, U.C. und Erdmann, E. (1998): Leitlinien zur Therapie der chronischen Herzinsuffizienz (Deutsche Gesellschaft für Kardiologie, Herz- und Kreislaufforschung), Z Kardiol, (Band 87), Seite 645-661. [74] Europäische_Gesellschaft_für_Kardiologie (1997): Die Behandlung der Herzinsuffizienz - Son-dergremium der Arbeitsgruppe "Herzinsuffizienz" der Europäischen Gesellschaft für Kardiologie, European Heart Journal, (Band 18), Seite 736-753. [75] The-CONSENSUS-Trial-Study-Group (1987): Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, (Band 316), No. 23, Seite 1429-35. [76] SOLVD-Investigators (1991): Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, (Band 325), No. 5, Seite 293-302. [77] Konstam, M. A.; Rousseau, M. F.; Kronenberg, M. W.; Udelson, J. E.; Melin, J.; Stewart, D.; Dolan, N.; Edens, T. R.; Ahn, S.; Kinan, D. und et al. (1992): Effects of the angio-tensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investiga-tors, Circulation, (Band 86), No. 2, Seite 431-8. [78] SOLVD-Investigators (1992): Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med, (Band 327), No. 10, Seite 685-91. [79] HOPE-Study-Investigators (2000): Effects of an angiotensin-converting enzyme inhibitor, ramipril, on car-diovascular events in high-risk patients, N Eng J Med, (Band 342), No. 145-153. [80] Pfeffer, M.A.; Braunwald, D.E. und Moye, L.A. (1992): Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - Results of the survival and ventricular enlargement trial, N Eng J Med, (Band 327), Seite 669-679. [81] Swedberg, K.; Held, P. und Kjekus, J. (1992): Effects of early administration of enalapril on mortality in patients with acute myocardial infarction - Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II), N Eng Med, (Band 327), Seite 678-684. [82] ELITE-II-Investigators (1999): Late breaking clinical tri-als, American Heart Association Scientific Ses-sion,

Atlanta/Georgia

. [83] Pitt, B.; Segal, R.; Martinez, F. A.; Meurers, G.; Cowley, A. J.; Thomas, I.; Deedwania, P. C.; Ney, D. E.; Snavely, D. B. und Chang, P. I. (1997): Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Eld-erly Study, ELITE), Lancet, (Band 349), No. 9054, Seite 747-52. [84] Rector, T. S.; Olivari, M. T.; Levine, T. B.; Francis, G. S. und Cohn, J. N. (1987): Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration, Am Heart J, (Band 114), No. 1 Pt 1, Seite 148-52. [85] Waagstein, F.; Bristow, M. R.; Swedberg, K.; Camerini, F.; Fowler, M. B.; Silver, M. A.; Gilbert, E. M.; Johnson, M. R.; Goss, F. G. und Hjalmarson, A. (1993): Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardio-myopathy (MDC) Trial Study Group, Lancet, (Band 342), No. 8885, Seite 1441-6. [86] CIBIS-Investigators (1994): A randomized trial of beta-blockade in heart failure. The Cardiac Insuffi-ciency Bisoprolol Study (CIBIS), Circulation, (Band 90), No. 4, Seite 1765-73. [87] Packer, M.; Bristow, M. R.; Cohn, J. N.; Colucci, W. S.; Fowler, M. B.; Gil-bert, E. M. und Shusterman, N. H. (1996): The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure, N Engl J Med, (Band 334), No. 21, Seite 1349-55. [88] MERIT-HF-Study-Group (1999): Effect of metoprolol CR/XL in chronic heart failure: meotoprolol CR/XL Randomized Interventional Trial in Congestive Haert Failure (MERIT-HF), Lancet, (Band 353), Seite 2001-2007. [89] CIBIS-II-Investigators-and-Committees (1999): The cardiac insufficiency Study II (CIBIS-II) - A randomized trial, Lancet, (Band 353), Seite 9-13. [90] Pitt, B.; Zannad, F.; Remme, W. J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J. und Wittes, J. (1999): The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investiga-tors, N Engl J Med, (Band 341), No. 10, Seite 709-17. [91] Weber, K. T. (1999): Aldosterone and spironolactone in heart failure, N Engl J Med, (Band 341), No. 10, Seite 753-5. [92] Ferguson, D.W. (1992): Digitalis and neurohumoral abnormalities in heart failure and implications for therapy, Am J Cardiol, (Band 69), No. Suppl., Seite 24G-32G. [93] The-Digitalis-Investigation-Group (1997): The effect of digoxin on mortality and morbidity in patients with heart failure, N Engl J Med, (Band 336), No. 8, Seite 525-33. [94] Packer, M.; Gheorgiade, M. und Young, J.B. (1993): Withdrawal of Dogoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme-inhibitors, N Eng J Med, (Band 329), Seite 1-7. [95] Uretsky, B.F.; Young, J.B. und Shahidi, F.E. (1993): Randomized study assessing the ef-fect of Digoxin withdrawal in patients with mild to moderate chronic congestiv heart failure: results of the PROVED trial, J Am Coll Cardiol, (Band 22), Seite 955-962. [96] Figulla, H. R.; Gietzen, F.; Zeymer, U.; Raiber, M.; Hegselmann, J.; Soballa, R. und Hilgers, R. (1996): Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Car-diomyopathy Trial, Circulation, (Band 94), No. 3, Seite 346-52. [97] Packer, M.; O'Connor, C. M.; Ghali, J. K.; Pressler, M. L.; Carson, P. E.; Belkin, R. N.; Miller, A. B.; Neuberg, G. W.; Frid, D.; Wertheimer, J. H.; Cropp, A. B. und DeMets, D. L. (1996): Effect of amlodipine on morbidity and mortality in severe chronic heart fail-ure. Prospective Randomized Amlodipine Survival Evaluation Study Group, N Engl J Med, (Band 335), No. 15, Seite 1107-14. [98] Cohn, J.N.; Ziesche, S. und Smith, R. (1997): Effects of the calcium antagonist felodipine as supplementary vasodilatator therapy in patients with chronic heart failure treated with enalapril (V-HeFT-III Study Group), Circulation, (Band 96), Seite 856-863. [99] Levine, T.B.; Bernink, P. und Caspi, A. (2000): Effect of mibefradil, a T-type calcium channel blocker on morbidity and mortality in moderate to severe congestive heart failure. The MACH-1 study, Circulation, (Band 101), Seite 758-764. [100] Packer, M. (2000): Prospective Randomized Amlodipine Survival Study-2. Late clinical trial results, American College of Cardiology Scientific Ses-sion,

Anaheim/California

. [101] Furberg, C. D. und Psaty, B. M. (1996): Calcium antagonists: Not appropriate as first line antihypertensive agents, Am J Hyper-tens, (Band 9), No. 2, Seite 122-5. [102] Furberg, C. D. und Psaty, B. M. (1996): Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health per-spective, Cardiovasc Drugs Ther, (Band 10), No. 4, Seite 463-6. [103] Baumann, G.; Felix, S.B. und Stangl, K. (1994): Therapy of cardiogenic shock, Z Kardiol, (Band 83), No. Suppl. 6, Seite 89-96. [104] Cohn, J.N.; Archibald, D.G. und Ziesche, S. (1986): Effects of vasodilatator therapy on mortality in chronic heart failure, N Eng J Med, (Band 314), Seite 1547-1552. [105] Cohn, J. N.; Johnson, G.; Ziesche, S.; Cobb, F.; Francis, G.; Tristani, F.; Smith, R.; Dunkman, W. B.; Loeb, H.; Wong, M. und et al. (1991): A comparison of enalapril with hydra-lazine-isosorbide dinitrate in the treatment of chronic congestive heart fail-ure, N Engl J Med, (Band 325), No. 5, Seite 303-10. [106] Ball, S. G. (2000): Discontinuation of doxazosin arm of ALLHAT - Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack, Lancet, (Band 355), No. 9214, Seite 1558. [107] Packer, M.; Carver, J.R. und Rodeheffer, R.J. (1991): Effect of oral Milrinone of mortality in severe chronic heart failure, N Eng J Med, (Band 325), Seite 1468-1475. [108] Betkowski, A.S. und Hauptman, P.J. (2000): Update on recent clinical trials in con-gestive heart failure, Curr Opin Cardiol, (Band 15), Seite 293-303. [109] Baumann, G. und Felix, S.B. (1991): Is the efficacy of positive inotropic drugs limited to symptomatic im-provement ?, Herz, (Band 16), No. 1, Seite 304-313. [110] Remme, W.J. und Kruijissen, H.A. (1994): Hemodynamic, neurohumoral and myocardial energetic effects of pimobendan, a novel calcium sensitizing com-pound, in patients with mild to moderate heart failure, J Cardiovasc Pharmacol, (Band 24), Seite 730-739. [111] Rapundalo, S.T.; Lathrop, D.A. und Harrison, S.A. (1988): Cyclic AMP-dependent and cyclic AMP-independent actions of novel cardiotonic agent, Arch Pharmacol, (Band 338), Seite 692-698. [112] Siegl, P.K. und Garcia, M.L. (1988): Interactions of DPI 201-106, a novel cardiotonic agent, with cardiac calcium, Arch Pharmacol, (Band 338), Seite 684-691. [113] The_Xamoterol_In_Severe_Heart_Hailure_Study_Group (1990): Xamoterol in severe heart fail-ure, Lancet, (Band 336), Seite 1-6. [114] Uretsky, B.F.; Jessup, M. und Konstam, M.A. (1990): Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart fail-ure, Circulation, (Band 82), Seite 774-780. [115] Tanimura, M.; Mishima, T.; Steinberg, M. I.; Borzak, S.; Goldstein, S. und Sabbah, H. N. (2000): Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure, Cardiovasc Drugs Ther, (Band 14), No. 1, Seite 77-82. [116] Cohn, L.N. (Dec 1999/ Jan 2000): Late-breaking clinical trial presented new research: MOXCON, Heart Failure Society News, Seite 5. [117] Abraham, W.T.; Oren, N.M. und Crisman, T.S. (1997): Effects of an oral , nonpeptide, selec-tive V2 receptor antagonist in patients with chronic heart failure, J Am Coll Cardiol, (Band 29), No. Suppl. A, Seite 169A. [118] Elsner, D.; Müntze, A.; Kromer, E.P. und Riegger, G.A. (1992): Effectiveness of endopeptidase inhibi-tion (candoxatril) in congestive heart failure, AM J Car-diol, (Band 82), Seite 196-201. [119] Kostis, J.B.; Rouleau, J.L. und Pfeffer, M.A. (2000): Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: evidence from the Omapatri-lat Heart Failure Program, J Am Coll Cardiol, (Band 35), No. Suppl. A, Seite 230A. [120] Sutsch, G.; Kiowski, W.; Yan, X. W.; Hunziker, P.; Christen, S.; Strobel, W.; Kim, J. H.; Rickenbacher, P. und Bertel, O. (1998): Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure, Circulation, (Band 98), No. 21, Seite 2262-8. [121] Sutsch, G.; Bertel, O. und Kiowski, W. (1997): Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans, Cardiovasc Drugs Ther, (Band 10), No. 6, Seite 717-25. [122] Benigni, A. und Remuzzi, G. (1999): Endothelin antagonists, Lancet, (Band 353), Seite 133-138. [123] Eizema, K.; Fechner, H.; Bezstarosti, K.; Schneider-Rasp, S.; van der Laarse, A.; Wang, H.; Schultheiss, H. P.; Poller, W. C. und Lamers, J. M. (2000): Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter, Circulation, (Band 101), No. 18, Seite 2193-9. [124] He, H.; Meyer, M.; Martin, J. L.; McDonough, P. M.; Ho, P.; Lou, X.; Lew, W. Y.; Hilal-Dandan, R. und Dillmann, W. H. (1999): Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)- ATPase activity and cardiac myocyte contrac-tility, Circulation, (Band 100), No. 9, Seite 974-80. [125] Shah, A. S.; White, D. C.; Tai, O.; Hata, J. A.; Wilson, K. H.; Pippen, A.; Kypson, A. P.; Glower, D. D.; Lefkowitz, R. J. und Koch, W. J. (2000): Adenovirus-mediated genetic manipu-lation of the myocardial beta- adrenergic signaling system in transplanted hearts, J Thorac Cardiovasc Surg, (Band 120), No. 3, Seite 581-8. [126] Kypson, A.; Hendrickson, S.; Akhter, S.; Wilson, K.; McDonald, P.; Lilly, R.; Dolber, P.; Glower, D.; Lefkowitz, R. und Koch, W. (1999): Adenovirus-mediated gene transfer of the beta2-adrenergic receptor to donor hearts enhances cardiac func-tion, Gene Ther, (Band 6), No. 7, Seite 1298-304. [127] Elkayam, U.; Berkley, R.; Azen, S.; Weber, L.; Geva, B. und Henry, W. L. (1983): Cardiac output by thermodilution technique. Effect of injectate's volume and temperature on accu-racy and reproducibility in the critically Ill patient, Chest, (Band 84), No. 4, Seite 418-22. [128] Bigger, J. T., Jr. (1997): Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Ar-tery Bypass Graft (CABG) - Patch Trial Investigators, N Engl J Med, (Band 337), No. 22, Seite 1569-75. [129] Leclercq, C.; Victor, F.; Alonso, C.; Pavin, D.; Revault d'Allones, G.; Ban-sard, J. Y.; Mabo, P. und Daubert, C. (2000): Comparative effects of permanent biventricular pacing for refractory heart failure in patients with stable sinus rhythm or chronic atrial fibrillation, Am J Car-diol, (Band 85), No. 9, Seite 1154-6, A9. [130] Leclercq, C.; Cazeau, S.; Ritter, P.; Alonso, C.; Gras, D.; Mabo, P.; Laza-rus, A. und Daubert, J. C. (2000): A pilot experience with permanent biventricular pacing to treat advanced heart failure, Am Heart J, (Band 140), No. 6, Seite 862-870. http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?, [131] Auricchio, A.; Stellbrink, C.; Sack, S.; Block, M.; Vogt, J.; Bakker, P.; Mortensen, P. und Klein, H. (1999): The Pacing Therapies for Congestive Heart Failure (PATH-CHF) study: Rationale, design, and endpoints of a prospective randomized multicenter study, Am J Cardiol, (Band 83), No. 5B, Seite 130D-135D. [132] Daubert, C.D. (2000): MUSTIC-Studie, Der Internist, (Band 41), Seite 1268. [133] Stellbrink, C.; Auricchio, A.; Butter, C.; Sack, S.; Vogt, J.; Bocker, D.; Block, M.; Kirkels, H. und Ramdat-Misier, A. (2000): Pacing therapies in congestive heart failure II study, Am J Cardiol, (Band 86), No. 9 Suppl 1, Seite K138-K143. [134] Hosenpud, J.D.; Bennett, L.E.; Keck, B.M.; Boucek, M.M. und Novick, R.J. (2000): The registry of the international society for heart and lung transplantation: seventeenth official re-port-2000, J Heart Lung Transplant, (Band 19), No. 10, Seite 909-31. [135] Mason, J. W.; O'Connell, J. B.; Herskowitz, A.; Rose, N. R.; McManus, B. M.; Billingham, M. E. und Moon, T. E. (1995): A clinical trial of immunosuppressive therapy for myocarditis - The Myocarditis Treatment Trial Investiga-tors, N Engl J Med, (Band 333), No. 5, Seite 269-75. [136] Herzum, M.; Ruppert, V.; Kuytz, B.; Jomaa, H.; Nakamura, I. und Maisch, B. (1994): Coxsackievirus B3 infection leads to cell death of cardiac myocytes, J Mol Cell Cardiol, (Band 26), No. 7, Seite 907-13. [137] Dörffel, W. V.; Felix, S. B.; Wallukat, G.; Brehme, S.; Bestvater, K.; Hof-mann, T.; Kleber, F. X.; Baumann, G. und Reinke, P. (1997): Short-term hemodynamic effects of immu-noadsorption in dilated cardiomyopathy, Circulation, (Band 95), No. 8, Seite 1994-7. [138] McNamara, D. M.; Rosenblum, W. D.; Janosko, K. M.; Trost, M. K.; Villa-neuva, F. S.; Demetris, A. J.; Murali, S. und Feldman, A. M. (1997): Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy, Circulation, (Band 95), No. 11, Seite 2476-8. [139] Gullestad, L.; Aass, H. und Fjeld, J. (2000): Effect of immunomodulating therapy with intravenous immunoglobulin in chronic heart failure, Coll Cardiol, (Band 35), No. Suppl. A, Seite 240A. [140] McNamara, D. (1999): Late-breaking clinical trial session., 3rd An-nual Scientific Meeting of the Heart Failure Society of America,

San Francisco

. [141] Bozkurt, B.; Torre-Amione, G. und Soran, O.Z. (2000): Safety and efficiacy of ENBREL (Etanercept) in the threatment of chronic heart failure, Am Coll Cardiol, (Band 35), No. Suppl. A, Seite 240A. [142] Miric, M.; Vasiljevic, J.; Bojic, M.; Popovic, Z.; Keserovic, N. und Pesic, M. (1996): Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic inter-feron alpha or thymic hormones initial results, Heart, (Band 75), No. 6, Seite 596-601. [143] Richter, W. O.; Jacob, B. G.; Ritter, M. M.; Suhler, K.; Vierneisel, K. und Schwandt, P. (1993): Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B anti-bodies, Metabolism, (Band 42), No. 7, Seite 888-94. [144] Schneider, K. M. (1998): Plasmapheresis and immunoadsorption: different techniques and their cur-rent role in medical therapy, Kidney Int Suppl, (Band 64), Seite S61-5. [145] Borberg, H.; Gaczkowski, A.; Hombach, V.; Oette, K. und Stoffel, W. (1988): Treatment of familial hypocholesterolemia by means of specific immunoadsorption, J Clin Apheresis, (Band 4), No. 2-3, Seite 59-65. [146] PlasmaSelect-AG (1999): Homepage, www.therasorb.com. [147] Müller-Derlich, J.; Moulin du, A. und Spaethe, R. (1993): Removal of human immunoglobulins with Ig-Therasorb, Transfusion Med, (Band 3), Seite 91. [148] Moulin du, A.; Muller-Derlich, J.; Bieber, F.; Richter, W. O.; Frei, U.; Muller, R. und Spaethe, R. (1993): Antibody-based immunoadsorption as a therapeutic means, Blood Purif, (Band 11), No. 3, Seite 145-9. [149] Schneider, M. (1996): Plasma- und Lymphapherese bei Immunopathien, Z Rheumatol, (Band 55), Seite 90-104. [150] Dwyer, J. (1992): Manipulating the immune system with immune globulin, N Eng J Med, (Band 326), Seite 107-116. [151] Schmid, E. R.; Schmidlin, D.; Tornic, M. und Seifert, B. (1999): Continuous thermodilution cardiac output: clinical validation against a reference technique of known accu-racy, Intensive Care Med, (Band 25), No. 2, Seite 166-72. [152] Lehmann, K. G. und Platt, M. S. (1999): Improved accuracy and precision of thermodilution cardiac output measurement using a dual thermistor catheter sys-tem, J Am Coll Cardiol, (Band 33), No. 3, Seite 883-91. [153] Mackenzie, J. D.; Haites, N. E. und Rawles, J. M. (1986): Method of assessing the reproducibil-ity of blood flow measurement: Factors influencing the performance of thermodi-lution cardiac output computers, Br Heart J, (Band 55), No. 1, Seite 14-24. [154] Conway, J. und Lund-Johannsen, P. (1991): Thermodiluation method for measur-ing cardiac output, Robertson, J. I. S., Cardiac Output Measurement, Saunders,

London

. [155] Schiller, N. B. (1991): Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommenda-tions of the American Society of Echocardiography, Circulation, (Band 84), No. 3 Suppl, Seite I280-7. [156] Cheitlin, M. D.; Alpert, J. S.; Armstrong, W. F.; Aurigemma, G. P.; Beller, G. A.; Bierman, F. Z.; Davidson, T. W.; Davis, J. L.; Douglas, P. S. und Gillam, L. D. (1997): ACC/AHA Guide-lines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in colloboration with the American Society of Echocardiography, Circulation, (Band 95), No. 6, Seite 1686-744. [157] Gola, A.; Pozzoli, M.; Capomolla, S.; Traversi, E.; Sanarico, M.; Cobelli, F. und Tavazzi, L. (1996): Comparison of Doppler echocardiography with thermodilution for assessing cardiac output in advanced congestive heart failure, Am J Cardiol, (Band 78), No. 6, Seite 708-12. [158] Wallukat, G. und Wollenberger, A. (1987): Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chrono-tropic beta adrenoceptor function in cultured neonatal rat heart myo-cytes, Biomed Biochim Acta, (Band 46), No. 8-9, Seite S634-9. [159] Aretz, H. T. (1987): Myocarditis: the Dallas criteria, Hum Pathol, (Band 18), No. 6, Seite 619-24. [160] Kühl, U.; Noutsias, M. und Schultheiss, H. P. (1995): Immunohistochemistry in dilated cardio-myopathy, Eur Heart J, (Band 16 Suppl O), Seite 100-6. [161] Tortoledo, F. A.; Quinones, M. A.; Fernandez, G. C.; Waggoner, A. D. und Winters, W. L., Jr. (1983): Quantification of left ventricular volumes by two-dimensional echocardiogra-phy: a simplified and accurate approach, Circulation, (Band 67), No. 3, Seite 579-84. [162] Naik, M. M.; Diamond, G. A.; Pai, T.; Soffer, A. und Siegel, R. J. (1995): Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardi-ography, radionuclide angiography and contrast cineangiography, J Am Coll Cardiol, (Band 25), No. 4, Seite 937-42. [163] Schiller, N. B.; Acquatella, H.; Ports, T. A.; Drew, D.; Goerke, J.; Ringertz, H.; Silverman, N. H.; Brundage, B.; Botvinick, E. H.; Boswell, R.; Carlsson, E. und Parmley, W. W. (1979): Left ventricular volume from paired biplane two-dimensional echocardiogra-phy, Circulation, (Band 60), No. 3, Seite 547-55. [164] van Royen, N.; Jaffe, C. C.; Krumholz, H. M.; Johnson, K. M.; Lynch, P. J.; Natale, D.; Atkinson, P.; Deman, P. und Wackers, F. J. (1996): Comparison and reproducibility of vis-ual echocardiographic and quantitative radionuclide left ventricular ejection frac-tions, Am J Cardiol, (Band 77), No. 10, Seite 843-50. [165] Vuille, C. und Weyman, A.E. (1994): Left ventricle. General considerations, assessement of chamber size and function, Weyman, A.E., Principles and Practice of Echocardiography, Seite 557-624, Lea & Feibiger,

Philadelphia

. [166] Feigenbaum, H. (1992): Echocardiography, Braunwald, E., Heart Disease, Seite 64-115, WB Saunders,

Philadelphia

. [167] Ross, J. Jr. (1998): Assessement of cardiac function and myocardial contractility, Alexander, R. W.;Schlant, R. C. und Fuster, V., Hurst´s The Heart, 9th. Auflage, Seite 727-743, McGraw-Hill,

New York

. [168] Rihal, C. S.; Nishimura, R. A.; Hatle, L. K.; Bailey, K. R. und Tajik, A. J. (1994): Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy - relation to symptoms and prognosis, Circulation, (Band 90), No. 6, Seite 2772-9. [169] Corrao, S.; Paterna, S.; Arnone, S.; Costa, R.; Amato, V.; Amico, G.; Scaglione, R. und Licata, G. (1995): Two-dimensional echocardiographic evaluation of left ventricular ejection fraction by the ellipsoid single-plane algorithm: a reliable method for assessing low or very low ejection fraction values?, Cardiology, (Band 86), No. 6, Seite 503-7. [170] Regnitz, V. und Rudolf, W. (1985): Dilatative Kardiomyopathie: Charakterisierung durch klinische und hämodynamische Befunde, Herz, (Band 10), Seite 125-133. [171] Müller, J.; Wallukat, G.; Dandel, M.; Bieda, H.; Brandes, K.; Spiegelsber-ger, S.; Nissen, E.; Kunze, R. und Hetzer, R. (2000): Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy, Circulation, (Band 101), No. 4, Seite 385-91. [172] Jin, O.; Sole, M. J.; Butany, J. W.; Chia, W. K.; McLaughlin, P. R.; Liu, P. und Liew, C. C. (1990): Detection of enterovirus RNA in myocardial biopsies from patients with myo-carditis and cardiomyopathy using gene amplification by polymerase chain reac-tion, Circulation, (Band 82), No. 1, Seite 8-16. [173] Limas, C. J. (1997): Cardiac autoantibodies in dilated cardiomyopathy: a pathogenetic role ?, Circulation, (Band 95), No. 8, Seite 1979-80. [174] Schulze, K.; Becker, B. F.; Schauer, R. und Schultheiss, H. P. (1990): Antibodies to ADP-ATP carrier - an autoantigen in myocarditis and dilated cardiomyopathy - impair cardiac function, Circulation, (Band 81), No. 3, Seite 959-69. [175] Wallukat, G.; Müller, J.; Podlowski, S.; Nissen, W.; Morwinski, R. und Het-zer, R. (1999): Agonist-like beta-adrenoceptor antibodies in heart failure, Am J Car-diol, (Band 17), No. 12A, Seite 75H-79H. [176] Müller, J.; Wallukat, G.; Weng, Y. G.; Dandel, M.; Spiegelsberger, S.; Sem-rau, S.; Brandes, K.; Theodoridis, V.; Loebe, M.; Meyer, R. und Hetzer, R. (1997): Weaning from me-chanical cardiac support in patients with idiopathic dilated cardiomyopa-thy, Circulation, (Band 96), No. 2, Seite 542-9. [177] Krum, H.; Sackner-Bernstein, J. D.; Goldsmith, R. L.; Kukin, M. L.; Schwartz, B.; Penn, J.; Medina, N.; Yushak, M.; Horn, E.; Katz, S. D. und et al. (1995): Double-blind, pla-cebo-controlled study of the long-term efficacy of carvedilol in patients with se-vere chronic heart failure, Circulation, (Band 92), No. 6, Seite 1499-506. [178] Carvedilol-Study-Group (1997): Randomised, placebo-controlled trial of carvedilol in patients with con-gestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group, Lancet, (Band 349), No. 9049, Seite 375-80. [179] Hahn, A. F. (2000): Intravenous immunoglobulin treatment in peripheral nerve disorders-- indica-tions, mechanisms of action and side-effects, Curr Opin Neurol, (Band 13), No. 5, Seite 575-82. [180] Hundt, M.; Manger, K.; Dorner, T.; Grimbacher, B.; Kalden, P.; Rascu, A.; Weber, D.; Burmester, G. R.; Peter, H. H.; Kalden, J. R. und Schmidt, R. E. (2000): Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous im-munoglobulin, Rheumatology (Oxford), (Band 39), No. 11, Seite 1301-1302. [181] Seneviratne, U. (2000): Guillain-Barre syndrome, Postgrad Med J, (Band 76), No. 902, Seite 774-782. [182] Felix, S.B.; Staudt, A.; Dörffel, W.V.; Stangl, V.; Merkel, K.; Pohl, M.; Döcke, W.; Morgera, S.; Neumayer, H.; Wernecke, D.; Wallukat, G.; Stangl, K. und Baumann, G. (2000): Hemodynamic Effects of Immunoadsorption and Subsequent Immunoglobu-lin Substitution in Dilated Cardiomyopathy, J Am Coll Cardiol, (Band 35), No. 6, Seite 1590-1598. [183] Ogi, M.; Yokoyama, H.; Tomosugi, N.; Hisada, Y. und Ohta, S. (1994): Risk factors for infec-tion and immunoglobulin replacement therapy in adult nephrotic syn-drom, Am J Kindney Dis, (Band 24), No. 3, Seite 427-36. [184] Yokoyama, T.; Vaca, L.; Rossen, R. D.; Durante, W.; Hazarika, P. und Mann, D. L. (1993): Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart, J Clin Invest, (Band 92), No. 5, Seite 2303-12. [185] Paydas, S.; Aksu, H. S.; Karademir, M. und Gurcay, A. A. (1991): Plasma levels of tumor necrosis factor alpha during hemodialysis, Nephron, (Band 57), No. 4, Seite 477-8. [186] Jorres, A.; Froese, P.; Fischer, C.; Safak, H.; Gahl, G. M.; Muller, C. und Vienken, J. (1992): Variables associated with the assessment of systemic tumor necrosis factor alpha levels during hemodialysis, Int J Artif Organs, (Band 15), No. 11, Seite 653-7. [187] Liu, L. und Zhao, S. P. (1999): The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy, Int J Car-diol, (Band 69), No. 1, Seite 77-82. [188] Milani, R. V.; Mehra, M. R.; Endres, S.; Eigler, A.; Cooper, E. S.; Lavie, C. J., Jr. und Ventura, H. O. (1996): The clinical relevance of circulating tumor necrosis factor-alpha in acute de-compensated chronic heart failure without cachexia, Chest, (Band 110), No. 4, Seite 992-5. [189] Kjekshus, H.; Smiseth, O. A.; Klinge, R.; Oie, E.; Hystad, M. E. und At-tramadal, H. (2000): Regulation of ET: pulmonary release of ET contributes to increased plasma ET levels and vasoconstriction in CHF, Am J Physiol Heart Circ Physiol, (Band 278), No. 4, Seite H1299-310. [190] Taddei, S.; Virdis, A.; Ghiadoni, L.; Sudano, I.; Notari, M. und Salvetti, A. (1999): Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension, Circulation, (Band 100), No. 16, Seite 1680-3. [191] Cracowski, J. L.; Stanke, F. und Bessard, G. (1999): Endothelin-1 and cardiovascular dis-eases, Rev Med Interne, (Band 20), No. 7, Seite 589-96. [192] Sakai, S.; Miyauchi, T.; Kobayashi, M.; Yamaguchi, I.; Goto, K. und Sugi-shita, Y. (1996): Inhibition of myocardial endothelin pathway improves long-term survival in heart fail-ure, Nature, (Band 384), No. 6607, Seite 353-5. [193] Krum, H.; Goldsmith, R.; Wilshire-Clement, M.; Miller, M. und Packer, M. (1995): Role of endothelin in the exercise intolerance of chronic heart failure, Am J Cardiol, (Band 75), No. 17, Seite 1282-3. [194] McMurray, J. J.; Ray, S. G.; Abdullah, I.; Dargie, H. J. und Morton, J. J. (1992): Plasma endothelin in chronic heart failure, Circulation, (Band 85), No. 4, Seite 1374-9. [195] Kiowski, W.; Sutsch, G.; Hunziker, P.; Muller, P.; Kim, J.; Oechslin, E.; Schmitt, R.; Jones, R. und Bertel, O. (1995): Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure, Lancet, (Band 346), No. 8977, Seite 732-6. [196] Bogoyevitch, M. A. und Sugden, P. H. (1996): The role of protein kinases in adapta-tional growth of the heart, Int J Biochem Cell Biol, (Band 28), No. 1, Seite 1-12. [197] Stawski, G.; Olsen, U. B. und Grande, P. (1991): Cytotoxic effect of endothelin-1 during 'stimulated' ischaemia in cultured myocytes, Eur J Phar-macol, (Band 201), No. 1, Seite 123-4. [198] Best, P. J. und Lerman, A. (2000): Endothelin in cardiovascular disease: from atherosclerosis to heart fail-ure [In Process Citation], J Cardiovasc Pharma-col, (Band 35), No. 4, Seite S61-63. [199] Ikenouchi, H.; Kangawa, K.; Matsuo, H. und Hirata, Y. (1997): Negative inotropic effect of adrenomedullin in isolated adult rabbit cardiac ventricular myo-cytes, Circulation, (Band 95), No. 9, Seite 2318-24. [200] Stangl, V.; Dschietzig, T.; Bramlage, P.; Boye, P.; Kinkel, H.; Staudt, A.; Baumann, G.; Felix, S. B. und Stangl, K. (2000): Adrenomedullin and myocardial con-tractility in the rat, Eur J Pharmacol, (Band 408), No. 1, Seite 83-9. [201] Del Bene, R.; Lazzeri, C.; Barletta, G.; Vecchiarino, S.; Guerra, C. T.; Fran-chi, F. und La Villa, G. (2000): Effects of low-dose adrenomedullin on cardiac function and systemic haemodynamics in man, Clin Physiol, (Band 20), No. 6, Seite 457-65. [202] Lainchbury, J. G.; Meyer, D. M.; Jougasaki, M.; Burnett, J. C., Jr. und Red-field, M. M. (2000): Effects of adrenomedullin on load and myocardial performance in normal and heart-failure dogs, Am J Physiol Heart Circ Physiol, (Band 279), No. 3, Seite H1000-6. [203] Kiesewetter, H.; Jung, F. und Spitzer, S. (1989): Die Fließeigenschaften des Blutes und ihre klinische Bedeutung beim arteriellen Gefäßpatienten, Der Internist, (Band 30), Seite 420-428. [204] Fadul, J. E.; Linde, T.; Sandhagen, B.; Wikstrom, B. und Danielson, B. G. (1997): Effects of extracor-poreal hemapheresis therapy on blood rheology, J Clin Apheresis, (Band 12), No. 4, Seite 183-6. [205] Fadul, J. E.; Danielson, B. G. und Wikstrom, B. (1996): Reduction of plasma fibrinogen, im-munoglobulin G, and immunoglobulin M concentrations by immunoadsorption therapy with tryptophan and phenylalanine adsorbents, Artif Organs, (Band 20), No. 9, Seite 986-90. [206] Chien, S.; Usami, S.; Dellenback, R. J. und Gregersen, M. I. (1970): Shear-dependent interaction of plasma proteins with erythrocytes in blood rheology, Am J Physiol, (Band 219), No. 1, Seite 143-53. [207] Brown, M. M. und Marshall, J. (1982): Effect of plasma exchange on blood viscosity and cerebral blood flow, Br Med J (Clin Res Ed), (Band 284), No. 6331, Seite 1733-6. [208] Burch, G. E. und Giles, T. D. (1972): Prolonged bed rest in the management of patients with cardio-myopathy, Cardiovasc Clin, (Band 4), No. 1, Seite 375-87. [209] Drucker, N. A.; Colan, S. D.; Lewis, A. B.; Beiser, A. S.; Wessel, D. L.; Ta-kahashi, M.; Baker, A. L.; Perez-Atayde, A. R. und Newburger, J. W. (1994): Gamma-globulin treatment of acute myocarditis in the pediatric population, Circulation, (Band 89), No. 1, Seite 252-7. [210] Hufnagel, G.; Pankuweit, S. und Maisch, B. (1998): Therapie der dilatativen Kardiomyopathy mit und ohne Entzündung, Medizinische Klinik, (Band 93), No. 3, Seite 240-251. [211] Tabet, J.; Logeart, D.; Geyer, C.; Guiti, C.; Ennezat, P. V.; Dahan, M. und Cohen-Solal, A. (2000): Comparison of the prognostic value of left ventricular filling and peak oxygen uptake in patients with systolic heart failure, Eur Heart J, (Band 21), No. 22, Seite 1864-1871. [212] Fuchs, J.B.; Werner, G. S.; Schulz, R. und Kreuzer, H. (1995): Prognostische Bedeutung von Ände-rungen der linksventrikulären diastolischen Funktion der dilatativen Kardiomyo-pathie, Z Kardiol, (Band 84), Seite 712-723. [213] Itoh, H.; Taniguchi, K.; Koike, A. und Doi, M. (1990): Evaluation of severity of heart failure using ventilatory gas analysis, Circulation, (Band 81), No. 1 Suppl, Seite II31-7. [214] Marburger, C. T.; Brubaker, P. H.; Pollock, W. E.; Morgan, T. M. und Kitz-man, D. W. (1998): Reproducibility of cardiopulmonary exercise testing in elderly patients with congestive heart failure, Am J Cardiol, (Band 82), No. 7, Seite 905-9. [215] Rostagno, C.; Galanti, G.; Comeglio, M.; Boddi, V.; Olivo, G. und Gastone Neri Serneri, G. (2000): Comparison of different methods of functional evaluation in patients with chronic heart failure, Eur J Heart Fail, (Band 2), No. 3, Seite 273-80. [216] Matsui, S.; Persson, M.; Fu, H.M.; Hayase, M. und Katsuda, S. (2000): Protektive Wirkung von Bisoprolol auf die Beta-1-Adrenozeptorpeptid induzierte Myokardschädi-gung bei Kaninchen, Herz, (Band 25), No. 3, Seite 267-270. [217] Magnusson, Y.; Wallukat, G.; Waagstein, F.; Hjalmarson, A. und Hoebeke, J. (1994): Autoimmunity in idio-pathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect, Circulation, (Band 89), No. 6, Seite 2760-7. [218] Sprung, C.L.; Rackow, E.C. und Civetta, J.M. (1988): Direkte Messungen mit Hilfe des Pulmona-larterienkatheters und abgeleitete Meßgrößen, Sprung, Charles L., Pulmonalarterienkatheter - Methodik und klinis-che Anwendung, Seite 102, Springer-Verlag,

Berlin; Heidelberg; New York

.